Experimental study of dynamic three-dimensional contrast-enhanced ultrasound in evaluating the inhibitory effect of regorafenib on the proliferation of incomplete ablation residual liver VX2 tumor
Experimental study of dynamic three-dimensional contrast-enhanced ultrasound in evaluating the inhibitory effect of regorafenib on the proliferation of incomplete ablation residual liver VX2 tumor
Objective:To observe the feasibility of three-dimensional contrast-enhanced ultrasound(3D-CEUS)in evaluating the inhibitory effect of regorafenib on incomplete ablation of residual cancer.Methods:The rabbits were randomly divided into 4 groups(n=5):incomplete ablation group(group A),incomplete ablation+targeted therapy group(group B),targeted therapy group(group C),and control group(group D).3D-CEUS was performed on the day before treatment and 7,14,21,28 d after treatment,and quantitative parameters were analyzed in vivo.VX2 tumors were taken out at the end of the experiment for cell proliferation index(Ki-67)and CD34 immunohistochemical staining,and microvessel density(MVD)was calculated.Results:At 21 and 28 days after treatment,the peak intensity(PI)of group B and C was significantly lower than that before treatment(P=0.046,0.033,respectively).Moreover,the PI of group B and group C were significantly different from that of group D(P=0.027,0.031,respectively).At 28 d after treatment,the ascending slope(S)of group B and group C was significantly lower than that of the control group(P=0.035,0.014,respectively).There was significant difference between group B and group A(P=0.027).At 28 d after treatment,there was no significant difference in Ki-67 proliferation index and MVD among the three groups(P＞0.05).Conclusion:Quantitative analysis parameters of 3D-CEUS can reflect the efficacy of regorafenib in inhibiting the proliferation of residual cancer after incomplete ablation of VX2 in situ orthotopic tumor.
万方数据